218 related articles for article (PubMed ID: 33994371)
1. Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.
Xiao L; Somers K; Murray J; Pandher R; Karsa M; Ronca E; Bongers A; Terry R; Ehteda A; Gamble LD; Issaeva N; Leonova KI; O'Connor A; Mayoh C; Venkat P; Quek H; Brand J; Kusuma FK; Pettitt JA; Mosmann E; Kearns A; Eden G; Alfred S; Allan S; Zhai L; Kamili A; Gifford AJ; Carter DR; Henderson MJ; Fletcher JI; Marshall G; Johnstone RW; Cesare AJ; Ziegler DS; Gudkov AV; Gurova KV; Norris MD; Haber M
Clin Cancer Res; 2021 Aug; 27(15):4338-4352. PubMed ID: 33994371
[TBL] [Abstract][Full Text] [Related]
2. The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
Xiao L; Karsa M; Ronca E; Bongers A; Kosciolek A; El-Ayoubi A; Revalde JL; Seneviratne JA; Cheung BB; Cheung LC; Kotecha RS; Newbold A; Bjelosevic S; Arndt GM; Lock RB; Johnstone RW; Gudkov AV; Gurova KV; Haber M; Norris MD; Henderson MJ; Somers K
Front Oncol; 2022; 12():863329. PubMed ID: 35677155
[TBL] [Abstract][Full Text] [Related]
3. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
[TBL] [Abstract][Full Text] [Related]
5. Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.
Waldeck K; Cullinane C; Ardley K; Shortt J; Martin B; Tothill RW; Li J; Johnstone RW; McArthur GA; Hicks RJ; Wood PJ
Int J Cancer; 2016 Jul; 139(1):194-204. PubMed ID: 26914605
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of an anti-tumor immune response with "chromatin-damaging" therapy.
Chen M; Brackett CM; Burdelya LG; Punnanitinont A; Patnaik SK; Matsuzaki J; Odunsi AO; Gudkov AV; Singh AK; Repasky EA; Gurova KV
Cancer Immunol Immunother; 2021 Jul; 70(7):2073-2086. PubMed ID: 33439292
[TBL] [Abstract][Full Text] [Related]
7. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z
PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799
[TBL] [Abstract][Full Text] [Related]
8. Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
Lock R; Carol H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Purmal A; Gudkov A; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27650817
[TBL] [Abstract][Full Text] [Related]
9. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
10. Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.
Hanmod SS; Wang G; Edwards H; Buck SA; Ge Y; Taub JW; Wang Z
Pediatr Blood Cancer; 2015 Jan; 62(1):52-9. PubMed ID: 25308916
[TBL] [Abstract][Full Text] [Related]
11. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.
Beider K; Bitner H; Voevoda-Dimenshtein V; Rosenberg E; Sirovsky Y; Magen H; Canaani J; Ostrovsky O; Shilo N; Shimoni A; Abraham M; Weiss L; Milyavsky M; Peled A; Nagler A
Biochem Pharmacol; 2019 Oct; 168():412-428. PubMed ID: 31325448
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of refractory metastatic neuroblastoma with panobinostat in combination with chemotherapy agents and iodine-131-meta-iodobenzylguanidine therapy.
Zareifar S; Shakibazad N; Zekavat OR; Bordbar M; Shahriari M
J Oncol Pharm Pract; 2020 Mar; 26(2):481-486. PubMed ID: 31156056
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.
McGuire JJ; Nerlakanti N; Lo CH; Tauro M; Utset-Ward TJ; Reed DR; Lynch CC
Int J Cancer; 2020 Nov; 147(10):2811-2823. PubMed ID: 32599665
[TBL] [Abstract][Full Text] [Related]
14. A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma.
Cheung BB; Kleynhans A; Mittra R; Kim PY; Holien JK; Nagy Z; Ciampa OC; Seneviratne JA; Mayoh C; Raipuria M; Gadde S; Massudi H; Wong IPL; Tan O; Gong A; Suryano A; Diakiw SM; Liu B; Arndt GM; Liu T; Kumar N; Sangfelt O; Zhu S; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM
Oncogene; 2021 Apr; 40(13):2367-2381. PubMed ID: 33658627
[TBL] [Abstract][Full Text] [Related]
15. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
16. Targeting FAcilitates Chromatin Transcription complex inhibits pleural mesothelioma and enhances immunotherapy.
Singh A; Pruett N; Dixit S; Gara SK; Wang H; Pahwa R; Schrump DS; Hoang CD
J Exp Clin Cancer Res; 2023 Nov; 42(1):304. PubMed ID: 37974213
[TBL] [Abstract][Full Text] [Related]
17. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
[TBL] [Abstract][Full Text] [Related]
18. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
20. Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer.
Wilson AJ; Gupta VG; Liu Q; Yull F; Crispens MA; Khabele D
Neoplasia; 2022 Feb; 24(2):63-75. PubMed ID: 34933276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
